Research fuels our mission to end cancer
Many of the greatest minds in cancer research are at MD Anderson. They're here because MD Anderson offers a unique environment that accelerates their ability to end cancer. They collaborate with other cancer experts – in different research areas and with the world's leading cancer doctors. Bright students and trainees contribute further to our dynamic research environment. Discoveries are fueled by vast research support and resources. Tomorrow's medicine is available to our patients first since we have the most cancer clinical trials in the world. These research efforts work in parallel to fight cancer through prevention, early diagnosis, effective therapies and scientific breakthroughs.
2019 CPRIT Funding
for core facility support
In August, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded more than $19 million to MD Anderson in support of research, recruitment and prevention efforts. MD Anderson and its projects have received $466.6 million, or 19.5%, of CPRIT’s total funding since the agency began making awards in 2009.
Departments, Labs and Institutes
MD Anderson has many parts, including departments, labs and institutes, but the sum of those parts is ending cancer. MD Anderson's reach is comprehensive when it comes to eliminating cancer.
Our laboratories cover the full breadth of cancer research. They’re led by some of the leading scientists and physicians in the world.
Scientists from different disciplines come together to focus on a common area in our research institutes.
Moon Shots Program
Inspired by an unprecedented era of scientific discovery a generation ago, the Moon Shots Program™ was launched by MD Anderson as an ambitious plan to make a giant leap in cancer research to benefit patients.Learn more about the Moon Shots Program
Pencil beam scans
Bladder cancer therapy
Boehringer Ingelheim and MD Anderson partner for virtual research and development center
Both organizations will conduct collaborative research to rapidly advance therapies for various types of cancers, including gastrointestinal and lung cancers. This multi-year partnership combines the drug-development capabilities of MD Anderson’s Therapeutics Discovery division with the innovative pipeline of novel medicines from Boehringer Ingelheim.
HPV-Related Oropharyngeal Cancers
New biomarker may help lower treatment intensity, reduce side effects for certain patients